- Hansa Biopharma (HNSA, Financial) reports a 39% increase in Q1 2025 product sales of IDEFIRIX®, generating 65.7 MSEK, up from 47.4 MSEK in Q1 2024. - Total revenue in Q1 2025 reached 66.3 MSEK, despite challenges in the organ allocation market. - Renée Aguiar-Lucander appointed as the new CEO.
Hansa Biopharma (HNSA, Financial) announced robust financial results for the first quarter of 2025, with IDEFIRIX® product sales totaling 65.7 MSEK, representing a 39% increase compared to the 47.4 MSEK reported in Q1 2024. The total revenue for the quarter reached 66.3 MSEK, marking a significant growth despite the unpredictable nature of the organ allocation market.
Operational highlights for the quarter included the completion of enrollment in the Post Authorization Efficacy and Safety (PAES) study and gaining market access in three additional European countries. The company also noted an increase in repeat use of IDEFIRIX® across key centers in Europe.
The quarter saw a positive development in financial performance, as operating loss narrowed to 93.4 MSEK from 159.4 MSEK in Q1 2024, showcasing improved operating efficiency. SG&A expenses decreased to 76.0 MSEK, while R&D expenses were reduced to 64.3 MSEK over the previous year.
As of Q1 2025, Hansa held cash and short-term investments of 250.2 MSEK. However, this reflects a decrease from 541.5 MSEK in the same quarter of the previous year. Net cash used in operations was reported at 151.9 MSEK.
In a strategic leadership move, Renée Aguiar-Lucander was appointed as the new CEO, taking over from Søren Tulstrup who stepped down after seven years with the company. This transition occurs as Hansa anticipates multiple pipeline catalysts in the second half of 2025, including pivotal data readouts from the U.S. ConfIdeS Phase 3 trial in kidney transplantation and the anti-GBM Phase 3 trial.
